Little Aldeyra's shares rocket higher as its first PhIII eye drug trial scores, clearing path to NDA
Aldeyra Therapeutics’ first foray into Phase III is a success, the eye drug developer said, setting it up for a potential NDA filing by the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.